Prostaglandin receptor EP2 protects dopaminergic neurons against 6-OHDA-mediated low oxidative stress

Neuroscience Letters

Volumn 441, Issue 1, 2008, Pages 44-49

  Carrasco, Emilce ^a   Werner, Peter ^a,b   Casper, Diana ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

6 OHDA; Butaprost; cAMP; Inflammation; Neuroprotection; Parkinson's disease; PGE2; PKA

Indexed keywords

ADENYLATE CYCLASE; BUTAPROST; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; FORSKOLIN; GUANINE NUCLEOTIDE BINDING PROTEIN; KT 5720; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; OXIDOPAMINE; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR EP2;

ANIMAL CELL; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RAT; SIGNAL TRANSDUCTION;

ADRENERGIC AGENTS; ALPROSTADIL; ANIMALS; CELLS, CULTURED; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EMBRYO, MAMMALIAN; ENZYME INHIBITORS; FORSKOLIN; HUMANS; MESENCEPHALON; NEURONS; OXIDATIVE STRESS; OXIDOPAMINE; RATS; RECEPTORS, PROSTAGLANDIN E; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 46149084859     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.05.111     Document Type: Article

References (36)

1. Abramovitz M., Adam M., Boie Y., Carriere M., Denis D., Godbout C., Lamontagne S., Rochette C., Sawyer N., Tremblay N.M., Belley M., Gallant M., Dufresne C., Gareau Y., Ruel R., Juteau H., Labelle M., Ouimet N., and Metters K.M. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim. Biophys. Acta 1483 (2000) 285-293
2. Akil M., Kolachana B.S., Rothmond D.A., Hyde T.M., Weinberger D.R., and Kleinman J.E. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J. Neurosci. 23 (2003) 2008-2013
3. Beyer C., and Karolczak M. Estrogenic stimulation of neurite growth in midbrain dopaminergic neurons depends on cAMP/protein kinase A signalling. J. Neurosci. Res. 59 (2000) 107-116
4. Bilak M., Wu L., Wang Q., Haughey N., Conant K., St Hillaire C., and Andreasson K. PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann. Neurol. 56 (2004) 240-248
5. Carlson N.G. Neuroprotection of cultured cortical neurons mediated by the cyclooxygenase-2 inhibitor APHS can be reversed by a prostanoid. J. Neurosci. Res. 71 (2003) 79-88
6. Carrasco E., Casper D., and Werner P. Dopaminergic neurotoxicity by 6-OHDA and MPP+: differential requirement for neuronal cyclooxygenase activity. J. Neurosci. Res. 81 (2005) 121-131
7. Carrasco E., Casper D., and Werner P. PGE(2) receptor EP1 renders dopaminergic neurons selectively vulnerable to low-level oxidative stress and direct PGE(2) neurotoxicity. J. Neurosci. Res. 85 (2007) 3109-3117
8. Carrasco E., and Werner P. Selective destruction of dopaminergic neurons by low concentrations of 6-OHDA and MPP+: protection by acetylsalicylic acid aspirin. Parkinsonism Relat. Disord. 8 (2002) 407-411
9. Chen C., and Bazan N.G. Lipid signaling: sleep, synaptic plasticity, and neuroprotection. Prostaglandins Other Lipid Mediat. 77 (2005) 65-76
10. Chijiwa T., Mishima A., Hagiwara M., Sano M., Hayashi K., Inoue T., Naito K., Toshioka T., and Hidaka H. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J. Biol. Chem. 265 (1990) 5267-5272
11. Chu Y., Kompoliti K., Cochran E.J., Mufson E.J., and Kordower J.H. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J. Comp. Neurol. 450 (2002) 203-214
12. Coleman R.A., Smith W.L., and Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46 (1994) 205-229
13. Echeverria V., Clerman A., and Dore S. Stimulation of PGE receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following beta-amyloid exposure. Eur. J. Neurosci. 22 (2005) 2199-2206
14. Frodin M., Peraldi P., and Van Obberghen E. Cyclic AMP activates the mitogen-activated protein kinase cascade in PC12 cells. J. Biol. Chem. 269 (1994) 6207-6214
15. Fujita H., Ogino T., Kobuchi H., Fujiwara T., Yano H., Akiyama J., Utsumi K., and Sasaki J. Cell-permeable cAMP analog suppresses 6-hydroxydopamine-induced apoptosis in PC12 cells through the activation of the Akt pathway. Brain Res. 1113 (2006) 10-23
16. Hartikka J., Staufenbiel M., and Lubbert H. Cyclic AMP, but not basic FGF, increases the in vitro survival of mesencephalic dopaminergic neurons and protects them from MPP(+)-induced degeneration. J. Neurosci. Res. 32 (1992) 190-201
17. Hirsch E.C., Hunot S., Damier P., and Faucheux B. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?. Ann. Neurol. 44 (1998) S115-S120
18. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev. 18 (1966) 244-253
19. Hulley P., Hartikka J., and Lubbert H. Cyclic AMP promotes the survival of dopaminergic neurons in vitro and protects them from the toxic effects of MPP+. J. Neural. Transm. Suppl. 46 (1995) 217-228
20. Jin J., Shie F.S., Liu J., Wang Y., Davis J., Schantz A.M., Montine K.S., Montine T.J., and Zhang J. Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein. J. Neuroinflamm. 4 (2007) 2
21. Kase H., Iwahashi K., Nakanishi S., Matsuda Y., Yamada K., Takahashi M., Murakata C., Sato A., and Kaneko M. K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. Biochem. Biophys. Res. Commun. 142 (1987) 436-440
22. Liu D., Wu L., Breyer R., Mattson M.P., and Andreasson K. Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann. Neurol. 57 (2005) 758-761
23. Malagelada C., Ryu E.J., Biswas S.C., Jackson-Lewis V., and Greene L.A. RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation. J. Neurosci. 26 (2006) 9996-10005
24. Mantamadiotis T., Lemberger T., Bleckmann S.C., Kern H., Kretz O., Martin Villalba A., Tronche F., Kellendonk C., Gau D., Kapfhammer J., Otto C., Schmid W., and Schutz G. Disruption of CREB function in brain leads to neurodegeneration. Nat. Genet. 31 (2002) 47-54
25. Mayr B., and Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat. Rev. Mol. Cell. Biol. 2 (2001) 599-609
26. McCullough L., Wu L., Haughey N., Liang X., Hand T., Wang Q., Breyer R.M., and Andreasson K. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J. Neurosci. 24 (2004) 257-268
27. McGeer P.L., Schulzer M., and McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47 (1996) 425-432
28. Michel P.P., and Agid Y. Chronic activation of the cyclic AMP signaling pathway promotes development and long-term survival of mesencephalic dopaminergic neurons. J. Neurochem. 67 (1996) 1633-1642
29. Mukherjee D., Nissen S.E., and Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286 (2001) 954-959
30. Narumiya S., Sugimoto Y., and Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79 (1999) 1193-1226
31. Schmidt U., Pilgrim C., and Beyer C. Differentiative effects of dopamine on striatal neurons involve stimulation of the cAMP/PKA pathway. Mol. Cell. Neurosci. 11 (1998) 9-18
32. Seamon K.B., Padgett W., and Daly J.W. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc. Natl. Acad. Sci. U.S.A. 78 (1981) 3363-3367
33. Shie F.S., Montine K.S., Breyer R.M., and Montine T.J. Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. Glia 52 (2005) 70-77
34. Sihag R.K., and Nixon R.A. Identification of Ser-55 as a major protein kinase A phosphorylation site on the 70-kDa subunit of neurofilaments. Early turnover during axonal transport. J. Biol. Chem. 266 (1991) 18861-18867
35. Takadera T., and Ohyashiki T. Prevention of rat cortical neurons from prostaglandin E2-induced apoptosis by glycogen synthase kinase-3 inhibitors. Neurosci. Lett. 400 (2006) 105-109
36. Takadera T., Yumoto H., Tozuka Y., and Ohyashiki T. Prostaglandin E(2) induces caspase-dependent apoptosis in rat cortical cells. Neurosci. Lett. 317 (2002) 61-64